Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Recommendation of “Moderate Buy” from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $245.9412.

JAZZ has been the subject of several research reports. Piper Sandler lifted their price target on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, May 22nd. Barclays upped their target price on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Finally, TD Cowen raised their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,098 shares of company stock worth $3,131,906 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Capital World Investors grew its stake in shares of Jazz Pharmaceuticals by 4.4% in the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after purchasing an additional 111,735 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares in the last quarter. Franklin Resources Inc. grew its position in Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after buying an additional 517,514 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 3.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock valued at $285,113,000 after buying an additional 50,996 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $0.64 during trading on Tuesday, reaching $244.81. The stock had a trading volume of 76,483 shares, compared to its average volume of 975,604. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The stock has a market cap of $15.38 billion, a PE ratio of -12,234.43, a P/E/G ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals has a one year low of $105.00 and a one year high of $246.07. The firm’s 50 day moving average price is $229.26 and its two-hundred day moving average price is $195.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, research analysts forecast that Jazz Pharmaceuticals will post 22.09 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.